BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 9357970)

  • 1. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies.
    Motta MR; Mangianti S; Rizzi S; Ratta M; Campanini E; Fortuna A; Fogli M; Tura S; Lemoli RM
    Exp Hematol; 1997 Nov; 25(12):1261-9. PubMed ID: 9357970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors.
    Lemoli RM; Gulati SC
    Exp Hematol; 1990 Oct; 18(9):1008-12. PubMed ID: 2397748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
    Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
    Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens.
    Bender JG; Lum L; Unverzagt KL; Lee W; Van Epps D; George S; Coon J; Ghalie R; McLeod B; Kaizer H
    Bone Marrow Transplant; 1994 Apr; 13(4):479-85. PubMed ID: 7517260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological characterization of CD34+ cells mobilized into peripheral blood.
    Lemoli RM; Tafuri A; Fortuna A; Catani L; Rondelli D; Ratta M; Tura S
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S47-50. PubMed ID: 9989890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
    Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S
    J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic bone marrow purging: is there any place for etoposide? In vitro comparison with mafosfamide.
    Olivieri A; Poloni A; Montanari M; Cantori I; Corvatta L; Masia MC; Curzi L; Mancini S; Leoni P
    J Hematother; 1997 Apr; 6(2):137-44. PubMed ID: 9131443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor.
    Lemoli RM; Tafuri A; Fortuna A; Petrucci MT; Ricciardi MR; Catani L; Rondelli D; Fogli M; Leopardi G; Ariola C; Tura S
    Blood; 1997 Feb; 89(4):1189-96. PubMed ID: 9028941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis.
    Chang TT; Gulati SC; Chou TC; Vega R; Gandola L; Ibrahim SM; Yopp J; Colvin M; Clarkson BD
    Cancer Res; 1985 Jun; 45(6):2434-9. PubMed ID: 3857119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte--macrophage colony-stimulating factor.
    Carlo-Stella C; Mangoni L; Piovani G; Almici C; Garau D; Caramatti C; Rizzoli V
    Bone Marrow Transplant; 1991 Oct; 8(4):265-73. PubMed ID: 1756324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.
    Fauth F; Martin H; Sonnhoff S; Bialleck H; Wiesneth M; Mihanovic B; Hoelzer D
    Bone Marrow Transplant; 2000 Apr; 25(8):831-6. PubMed ID: 10808203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cumulative chemotherapy increases mafosfamide toxicity for normal progenitor cells in AML patients: rationale for cryopreserving adapted-dose purged marrow early in first complete remission.
    Martin H; Bruecher J; Claudé R; Hoelzer D
    Bone Marrow Transplant; 1993 Nov; 12(5):495-9. PubMed ID: 8298560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro chemosensitivity of leukemic progenitor cells (AML-CFU) to a combination of mafosfamide lysine (ASTA-Z 7654) and etoposide (VP16-213).
    Deconinck E; Tamayo E; Hervé P
    Bone Marrow Transplant; 1990 Jan; 5(1):13-8. PubMed ID: 2297586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors.
    Carlo-Stella C; Tabilio A; Regazzi E; Garau D; La Tagliata R; Trasarti S; Andrizzi C; Vignetti M; Meloni G
    Bone Marrow Transplant; 1997 Sep; 20(6):465-71. PubMed ID: 9313879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of in vitro inhibition of etoposide (VP16) on leukemic and normal myeloid, erythroid clonogenic cells.
    Lagneaux L; Marie JP; Delforge A; Socquet M; Thevenin D; Zittoun R; Stryckmans P
    Exp Hematol; 1989 Aug; 17(7):843-6. PubMed ID: 2753092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow.
    Tamayo E; Hervé P
    Exp Hematol; 1988 Feb; 16(2):97-101. PubMed ID: 3276544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative cytotoxicity of various drug combinations for human leukemic cells and normal hematopoietic precursors.
    Chang TT; Gulati S; Chou TC; Colvin M; Clarkson B
    Cancer Res; 1987 Jan; 47(1):119-22. PubMed ID: 3466686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.